King Pharmaceuticals Inc.

(NYSE:KG)

View:
Quarterly Data
Annual Data
Note: All numbers in thousands

	Mar 31, 2010	Dec 31, 2009	Sep 30, 2009	Jun 30, 2009
Operating revenue
Total Revenue	380,855	439,106	463,349	444,988
Operating Revenue	380,855	439,106	463,349	444,988
Adjustments To Revenue	—	—	—	—
Cost Of Sales	184,329	-59,145	216,146	208,955
Cost Of Sales With Depreciation	127,054	152,935	162,797	156,093
Gross Operating Profit	196,526	498,251	247,203	236,033
Operating Expenses
Research And Development Expenses	28,324	27,554	22,640	21,202
Selling General And Administrative Expenses	140,475	138,983	134,315	122,378
Advertising Expenses	—	1,204	1,427	1,197
Operating Income Before Depreciation	27,727	330,510	88,821	91,256
Operating Income	27,465	52,265	87,168	89,781
Depreciation	—	267,013	—	—
Depreciation Unreconciled	57,275	54,933	53,349	52,862
Amortization	—	—	—	—
Amortization Of Intangibles	—	—	—	—
Operating Income After Depreciation	27,727	63,497	88,821	91,256
Non Operating Expenses
Interest Expense	8,736	15,310	22,218	27,592
Pre Tax Income	18,063	32,059	68,024	67,283
Income Taxes	13,594	9,807	25,536	29,348
Minority Interest	—	—	—	—
Income Before Income Taxes	18,063	32,059	68,024	67,283
Net Income From Continuing Operations	4,469	22,252	42,488	37,935
Net Income From Discontinued Operations	—	—	—	—
Net Income From Total Operations	4,469	22,252	42,488	37,935
Non Recurring Events
Extraordinary Income Losses	—	—	—	—
Income From Cummulated Effect Of Accounting Changes	—	—	—	—
Income From Tax Loss Carryforward	—	—	—	—
Other Gains And Losses	—	—	—	—
Total Net Income	4,469	22,252	42,488	37,935
Normalized Income	4,731	33,484	44,141	39,410
NetIncome Available For Common	4,469	22,252	42,488	37,935
Preferred Dividends	—	—	—	—
Excise Taxes	—	—	—	—

	Dec 31, 2009	Dec 31, 2008	Dec 31, 2007	Dec 31, 2006
Operating revenue
Total Revenue	1,776,500	1,565,061	2,136,882	1,988,500
Operating Revenue	1,776,500	1,565,061	2,136,882	1,988,500
Adjustments To Revenue	—	—	—	—
Cost Of Sales	570,244	392,677	564,477	416,934
Cost Of Sales With Depreciation	622,764	394,825	566,534	419,808
Gross Operating Profit	1,206,256	1,172,384	1,572,405	1,571,566
Operating Expenses
Research And Development Expenses	98,652	145,173	149,425	143,596
Selling General And Administrative Expenses	536,601	446,020	691,034	713,965
Advertising Expenses	5,226	—	—	—
Operating Income Before Depreciation	565,777	581,191	731,946	714,005
Operating Income	236,354	-219,645	227,513	402,546
Depreciation	267,013	152,861	175,920	150,423
Depreciation Unreconciled	214,493	150,713	173,863	147,549
Amortization	—	—	—	—
Amortization Of Intangibles	—	—	—	—
Operating Income After Depreciation	298,764	428,330	556,026	563,582
Non Operating Expenses
Interest Expense	88,223	7,943	7,818	9,857
Pre Tax Income	150,589	-201,704	250,818	424,312
Income Taxes	58,636	131,359	67,600	135,730
Minority Interest	—	—	—	—
Income Before Income Taxes	150,589	-201,704	250,818	424,312
Net Income From Continuing Operations	91,953	-333,063	183,218	288,582
Net Income From Discontinued Operations	—	—	-237	367
Net Income From Total Operations	91,953	-333,063	182,981	288,949
Non Recurring Events
Extraordinary Income Losses	—	—	—	—
Income From Cummulated Effect Of Accounting Changes	—	—	—	—
Income From Tax Loss Carryforward	—	—	—	—
Other Gains And Losses	—	—	—	—
Total Net Income	91,953	-333,063	182,981	288,949
Normalized Income	154,363	314,912	511,731	448,990
NetIncome Available For Common	91,953	-333,063	183,218	288,582
Preferred Dividends	—	—	—	—
Excise Taxes	—	—	—	—

- Advertisement -